<DOC>
	<DOCNO>NCT01454544</DOCNO>
	<brief_summary>The primary aim trial evaluate efficacy ALK house dust mite tablet give daily compare placebo tablet treatment house dut mite allergic rhinits . Additionally secondary objective trial evaluate safety tolarability ALK house dust mite tablet . Immunotherapy show provide therapeutic benefit subject house dust mite induce allergy . This trial plan investigate clinically relevant improvement rhinitis symptom less use symptomatic medication obtain subject history poor didease control despite use symptomatic medication .</brief_summary>
	<brief_title>A One Year Trial Evaluating Safety Efficacy ALK House Dust Mite Allergy Tablet</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>A history house dust mite allergy Use symptomatice medication treatment house dust mite allergy Positive skin prick test mite Positive specific IgE History uncontrolled asthma Overlapping symptomatice allergy Previous treatment immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>